Blue Star Ltd reported a robust Q2 FY27 performance with revenue climbing to Rs 2,930.95 crore and net profit rising to Rs 123.91 crore. Growth was driven by strong results in its electro-mechanical projects and unitary products segments. While half-year figures were bolstered by Rs 32.19 crore in exceptional gains from asset sales, the core operational strength suggests continued momentum for the HVAC and commercial refrigeration major.
Blue Star Q2 Net Profit Grows to Rs 123.91 Crore
Revenue increased to Rs 2,930.95 crore from Rs 2,422.37 crore in Q2 FY26.
Net profit rose to Rs 123.91 crore from Rs 98.78 crore in the year-ago period.
Reader Takeaway: Revenue and profit grew on strong segment demand, though investors should account for one-time gains.
What just happened
Blue Star Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant jump in consolidated revenue to Rs 2,930.95 crore, up from Rs 2,422.37 crore in the same quarter last year. Consolidated net profit reached Rs 123.91 crore compared to Rs 98.78 crore in the corresponding period of FY26.
Why this matters
The results highlight consistent demand across the company's core divisions. The electro-mechanical projects and commercial AC segment led the revenue contribution at Rs 1,935.99 crore, followed by the unitary products segment, which generated Rs 897.66 crore. This growth signals that the company is effectively navigating market competition in the HVAC and cooling solutions space.
Exceptional Items
For the half-year, the group recorded exceptional income totaling Rs 32.19 crore. This includes a gain of Rs 23.02 crore from the divestment of its Medtech business by its subsidiary, Blue Star Engineering & Electronics Limited, and a Rs 9.17 crore profit from the sale of a property by the parent company. Investors should note that these items inflate the half-year bottom line compared to core operations.
What to track next
Shareholders should look for sustained margins in the unitary products segment. While the sale of the Medtech business streamlines the company's focus, the ability to maintain project execution pace in the electro-mechanical segment will be the primary driver for future quarters.